荷兰肺癌按分期、组织学与一线治疗模式的医疗费用(2012-2021年)
研究将荷兰居民2013-2021年医疗支出与137,129例2012-2021年发病的肿瘤登记数据链接,按治疗阶段、分期和组织学估算肺癌归因费用。全路径人均费用为48,443欧元,IV期初始治疗月费用8,293欧元,显著高于IA期的3,228欧元;2018-2021年IV期初始和持续治疗月费用较2013-2017年分别上升55%和148%。
要点
- 肺癌全治疗路径人均费用为48,443欧元。
- IV期初始治疗月费用8,293欧元,IA期为3,228欧元。
- 2018-2021年IV期初始和持续治疗月费用较2013-2017年分别上升55%和148%。
核心结论
- 治疗进展正在快速推高晚期肺癌的医疗费用。
- 政策制定者应仔细评估新型治疗的成本效益,并将分期特异性治疗费用纳入早期检测干预的评估。
研究设计与样本
- 将荷兰居民2013-2021年个人医疗支出与肿瘤登记数据链接,纳入2012-2021年发病的肿瘤病例137,129例。
- 按治疗阶段(初始、持续、终末)、癌症分期和组织学估算肺癌归因费用,并观察医疗费用随时间的变化趋势。
主要发现
- 肺癌全治疗路径人均费用为48,443欧元。
- 总医疗费用在初始阶段最高,其次为终末阶段和持续阶段。
- IV期肺癌初始治疗月费用为8,293欧元,IA期为3,228欧元。
- 2018-2021年IV期肺癌初始治疗月费用较2013-2017年上升55%,持续治疗月费用上升148%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Lung cancer is a leading cause of mortality worldwide, with lung cancer treatment presenting a significant financial burden. The treatment landscape has recently shifted, seeing an increase in targeted- and immunotherapies. Such treatments are expensive, but estimates of the medical costs of the lung cancer treatment pathway largely predate their introduction. METHODS: We link medical expenditures of individuals resident in the Netherlands (n = 19.2 m) for 2013-2021 to tumour-level (n = 137,129, incident 2012-2021) Netherlands Cancer Registry data. We estimate lung cancer-attributable costs by phase of care (initial, continuing and terminal), stratified by cancer stage and histology, and observe trends in medical costs over time. RESULTS: We estimate mean costs over the lung cancer treatment pathway to be €48,443 per patient. Total medical costs are highest in the initial phase, followed by the terminal and continuing phase. Monthly treatment for stage IV lung cancer is significantly more expensive than for early-stage disease (€8293 per month of initial care relative to €3228 for stage IA). Stage IV lung cancer has become significantly more expensive to treat 2018-2021 relative to 2013-2017, with monthly expenditures rising 55 % in initial care and 148 % in continuing care. Population-wide, we find €900.6 million spent on lung cancer care in 2021, €433 million more than in 2016, of which €307.3 million is attributed to per-patient expenditure trends. CONCLUSIONS: Treatment advances are quickly inflating medical costs for late-stage lung cancer. Policy makers should carefully evaluate the cost-effectiveness of novel treatments, and incorporate stage-specific treatment costs in evaluating interventions for early detection.
引用
- de Nijs K, de Koning HJ, van der Aalst C, et al. Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012-2021). Eur J Cancer. 2024. PMID: 39047534. doi:10.1016/j.ejca.2024.114231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。